Influence of Substance Use Disorder on Treatment Retention of Adult-Attention-Deficit/Hyperactive Disorder Patients. A 5-Year Follow-Up Study.

adult attention-deficit/hyperactivity disorder substance use disorder survival in treatment

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
05 May 2021
Historique:
received: 25 03 2021
revised: 27 04 2021
accepted: 01 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most widespread neurodevelopmental disorder, and it still persists into adulthood in 2-6% of the population. Psychiatric comorbidities are very common in adult ADHD (A-ADHD) patients; in particular, Substance Use Disorder (SUD) is found in 40% of these patients. Co-occurrence of ADHD and SUD is described as detrimental to clinical outcome by many authors, while only a few studies describe good clinical results in A-ADHD-SUD patients when they were treated for ADHD, both for the efficacy and the compliance of patients. In this study we tested to determine whether SUD can influence the treatment outcome of A-ADHD patients by correlating lifetime, past and current substance use in A-ADHD patients with their outcome (retention rate) during a 5-year follow-up of patients treated with stimulant and non-stimulant medications, using Kaplan-Meier survival analysis with overall and pairwise comparison. The association between demographic, symptomatological and clinical aspects with retention in treatment, adjusting for potential confounding factors, was summarized using Cox regression. After 5 years of observation, the cumulative treatment retention was 49.0%, 64.3% and 41.8% for A-ADHD patients without lifetime SUD (NSUD/A-ADHD), A-ADHD with past SUD (PSUD/A-ADHD) and A-ADHD with current SUD (CSUD/A-ADHD), respectively. Overall comparisons were not significant (Wilcoxon Rank-Sum (statistical) Test = 1.48; df = 2;

Identifiants

pubmed: 34063121
pii: jcm10091984
doi: 10.3390/jcm10091984
pmc: PMC8124852
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Expert Opin Pharmacother. 2019 Feb;20(3):343-355
pubmed: 30513231
J Child Psychol Psychiatry. 2012 Mar;53(3):304-12
pubmed: 22066497
J Clin Psychiatry. 2013 Oct;74(10):983-90
pubmed: 24229749
Curr Psychiatry Rep. 2014 Mar;16(3):436
pubmed: 24526271
Br J Pharmacol. 2008 May;154(2):327-42
pubmed: 18345022
Atten Defic Hyperact Disord. 2015 Jun;7(2):115-28
pubmed: 25987323
Am J Drug Alcohol Abuse. 2006;32(4):629-35
pubmed: 17127551
Am J Addict. 2007;16 Suppl 1:14-21; quiz 22-3
pubmed: 17453603
Eur Neuropsychopharmacol. 2017 Nov;27(11):1144-1152
pubmed: 28935267
Neuropsychiatr Dis Treat. 2014 Aug 22;10:1543-69
pubmed: 25187718
Am J Addict. 2014 Mar-Apr;23(2):189-93
pubmed: 25187055
Addict Behav. 2014 Aug;39(8):1278-85
pubmed: 24821471
Ann N Y Acad Sci. 2001 Jun;931:1-16
pubmed: 11462736
Neuropharmacology. 2014 Jan;76 Pt B:276-86
pubmed: 23639436
Lancet. 1999 Dec 18-25;354(9196):2132-3
pubmed: 10609822
Addiction. 2014 Mar;109(3):440-9
pubmed: 24118269
J Child Psychol Psychiatry. 2011 Feb;52(2):139-47
pubmed: 20854363
J Affect Disord. 2013 May;147(1-3):80-6
pubmed: 23218897
Harv Rev Psychiatry. 2017 Mar/Apr;25(2):50-64
pubmed: 28272130
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Expert Rev Clin Pharmacol. 2020 Nov;13(11):1271-1280
pubmed: 33040639
Psychol Psychother. 2021 Apr;94 Suppl 2:426-463
pubmed: 32515537
Int J Environ Res Public Health. 2019 Oct 15;16(20):
pubmed: 31618876
Disabil Rehabil. 2014;36(2):146-54
pubmed: 23586698
CMAJ. 2003 Mar 18;168(6):715-22
pubmed: 12642429
J Subst Abuse Treat. 2013 Feb;44(2):224-30
pubmed: 22889694
J Affect Disord. 2005 Oct;88(2):217-33
pubmed: 16125784
Cell. 2015 Aug 13;162(4):712-25
pubmed: 26276628
J Clin Psychopharmacol. 2012 Oct;32(5):645-52
pubmed: 22926598
Eur Neuropsychopharmacol. 2013 Dec;23(12):1714-23
pubmed: 23731497
Int J Environ Res Public Health. 2020 May 17;17(10):
pubmed: 32429586
Eur Addict Res. 2020;26(4-5):223-232
pubmed: 32634814
J Clin Psychol. 2001 Jun;57(6):815-28
pubmed: 11344467
Bioessays. 2010 Sep;32(9):748-55
pubmed: 20730946
J Atten Disord. 2020 Jun 3;:1087054720930816
pubmed: 32486881
Arch Gen Psychiatry. 2003 Jul;60(7):709-17
pubmed: 12860775
J Psychopharmacol. 2015 Jan;29(1):15-23
pubmed: 25142405
Drug Alcohol Depend. 2013 Sep 1;132(1-2):127-33
pubmed: 23415849
Harv Rev Psychiatry. 1997 Jan-Feb;4(5):231-44
pubmed: 9385000
J Clin Psychopharmacol. 2016 Jun;36(3):222-8
pubmed: 27043119
Neuropsychiatry (London). 2012 Aug;2(4):301-312
pubmed: 23105949
World J Biol Psychiatry. 2010 Aug;11(5):709-18
pubmed: 20353312
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449

Auteurs

Alessandro Pallucchini (A)

PISA-School of Clinical and Experimental Psychiatry, 56100 Pisa, Italy.

Marco Carli (M)

Department of Clinical and Experimental Medicine, School of Clinical Pharmacology, University of Pisa, 56100 Pisa, Italy.

Angelo G I Maremmani (AGI)

PISA-School of Clinical and Experimental Psychiatry, 56100 Pisa, Italy.
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), 55045 Pietrasanta, Italy.
North-Western Tuscany Local Health Unit, Department of Psychiatry, Tuscany NHS, Versilia Zone, 55049 Viareggio, Italy.

Marco Scarselli (M)

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56100 Pisa, Italy.

Giulio Perugi (G)

Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, 56100 Pisa, Italy.

Icro Maremmani (I)

Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), 55045 Pietrasanta, Italy.
Vincent P. Dole Dual Diagnosis Unit, Department of Neurosciences, Santa Chiara University Hospital, University of Pisa, 56100 Pisa, Italy.
G. De Lisio Institute of Behavioral Sciences, 56100 Pisa, Italy.
Saint Camillus International University of Health and Medical Sciences-UniCamillus, 00131 Rome, Italy.

Classifications MeSH